CRISPR/Cas9 genome editing was applied to disrupt CD38 during amplification, showing that CD38 CAR-NK cell fratricide reduced and augmented abilities to target primary acute myeloblastic leukemia (AML) blasts [115]. The gene discussed is CD38; the disease is acute myeloid leukemia.